Urinary tract infections in patients with renal insufficiency and dialysis - epidemiology, pathogenesis, clinical symptoms, diagnosis and treatment.

GMS infectious diseases Pub Date : 2021-12-21 eCollection Date: 2021-01-01 DOI:10.3205/id000076
Jürgen E Scherberich, Reinhard Fünfstück, Kurt G Naber
{"title":"Urinary tract infections in patients with renal insufficiency and dialysis - epidemiology, pathogenesis, clinical symptoms, diagnosis and treatment.","authors":"Jürgen E Scherberich, Reinhard Fünfstück, Kurt G Naber","doi":"10.3205/id000076","DOIUrl":null,"url":null,"abstract":"<p><p>Epidemiological studies show an increasing number of patients worldwide suffering from chronic kidney diseases (CKD), which are associated with a risk for progression to end-stage kidney disease (ESKD). CKD patients stage 2-5, patients with regular chronic dialysis treatment (hemo- or peritoneal dialysis), and patients suffering from kidney allograft dysfunction are at high risk to develop infections, e.g. urinary tract infections (UTI) and/or sepsis (urosepsis). These groups show metabolic disturbance, chronic inflammation, and impaired immunocompetence. <i>Escherichia coli</i> is still the most common pathogen in UTI. A wide variety of other pathogens may be involved in UTI. Urological interventions, catheterization, as well as repeated courses of antibiotics contribute to an increased challenge of antimicrobial resistance. The diagnosis of UTI in CKD is based on standard clinical and laboratory criteria. Pyuria (≥10 leucocytes/µl) is more often observed in patients with oligoanuria and low bacterial colony counts. The treatment strategies for this population are based on the same principles as in patients with normal renal function. However, drugs cleared by the kidney or by dialysis membranes need dose adjustment. Antimicrobials with potential systemic toxicity and nephrotoxicity should be administered with caution.</p>","PeriodicalId":91688,"journal":{"name":"GMS infectious diseases","volume":"9 ","pages":"Doc07"},"PeriodicalIF":0.0000,"publicationDate":"2021-12-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8777485/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"GMS infectious diseases","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3205/id000076","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2021/1/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Epidemiological studies show an increasing number of patients worldwide suffering from chronic kidney diseases (CKD), which are associated with a risk for progression to end-stage kidney disease (ESKD). CKD patients stage 2-5, patients with regular chronic dialysis treatment (hemo- or peritoneal dialysis), and patients suffering from kidney allograft dysfunction are at high risk to develop infections, e.g. urinary tract infections (UTI) and/or sepsis (urosepsis). These groups show metabolic disturbance, chronic inflammation, and impaired immunocompetence. Escherichia coli is still the most common pathogen in UTI. A wide variety of other pathogens may be involved in UTI. Urological interventions, catheterization, as well as repeated courses of antibiotics contribute to an increased challenge of antimicrobial resistance. The diagnosis of UTI in CKD is based on standard clinical and laboratory criteria. Pyuria (≥10 leucocytes/µl) is more often observed in patients with oligoanuria and low bacterial colony counts. The treatment strategies for this population are based on the same principles as in patients with normal renal function. However, drugs cleared by the kidney or by dialysis membranes need dose adjustment. Antimicrobials with potential systemic toxicity and nephrotoxicity should be administered with caution.

Abstract Image

Abstract Image

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
肾功能不全和透析患者的尿路感染--流行病学、发病机制、临床症状、诊断和治疗。
流行病学研究表明,全球慢性肾脏病(CKD)患者人数不断增加,并有发展为终末期肾脏病(ESKD)的风险。2-5 期 CKD 患者、定期接受慢性透析治疗(血液透析或腹膜透析)的患者以及肾脏异体移植功能障碍患者发生感染(如尿路感染和/或败血症)的风险很高。这些人群表现出代谢紊乱、慢性炎症和免疫功能受损。大肠杆菌仍然是UTI 中最常见的病原体。其他多种病原体也可能与尿毒症有关。泌尿科介入治疗、导尿以及反复使用抗生素都增加了抗菌药耐药性的挑战。慢性肾脏病患者尿毒症的诊断基于标准的临床和实验室标准。在少尿症和细菌菌落计数较低的患者中更常观察到脓尿(≥10 个白细胞/µl)。这类患者的治疗策略与肾功能正常患者的治疗原则相同。不过,经肾脏或透析膜清除的药物需要调整剂量。应慎用具有潜在全身毒性和肾毒性的抗菌药物。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
审稿时长
17 weeks
期刊最新文献
Trichosporon infection in chronic kidney disease patients from a tertiary care hospital - a case series or an outbreak? An unanswered question but a well-managed problem. Fusarium spp.: infections and intoxications. A complex case of bacterial pericarditis caused by a new pathogenic agent. The interpretation of COVID-19 in cause-of-death statistics: a matter of causality. Therapeutic strategies for uncomplicated cystitis in women.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1